Mercer Global Advisors Inc. ADV Makes New $209,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mercer Global Advisors Inc. ADV bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, Holdings Channel reports. The institutional investor bought 2,606 shares of the medical equipment provider’s stock, valued at approximately $209,000.

A number of other large investors also recently modified their holdings of the business. UMB Bank n.a. grew its stake in Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 247 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of Lantheus in the 1st quarter worth about $34,000. FinTrust Capital Advisors LLC lifted its position in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 232 shares during the last quarter. Finally, NBC Securities Inc. boosted its stake in Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 191 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH opened at $105.84 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm’s 50 day moving average is $104.36 and its 200-day moving average is $86.40. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The stock has a market capitalization of $7.34 billion, a P/E ratio of 16.16 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.40 EPS. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Truist Financial reduced their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. JMP Securities reduced their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Finally, Leerink Partners raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Activity at Lantheus

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares of the company’s stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock worth $3,922,001 in the last quarter. 1.50% of the stock is owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.